Robotic Versus Open Surgery Following Neoadjuvant Therapy In Pancreatic Cancer: Evaluation Of Safety And Oncologic Outcomes

Study Overview

Robotic Versus Open Surgery Following Neoadjuvant Therapy in Pancreatic Cancer: Evaluation of Safety and Oncologic Outcomes

The feasibility and safety of minimally invasive surgery in cases after neoadjuvant therapy were unclear. It is worth exploring the safety of robotic resection for pancreatic cancer following neoadjuvant therapy. The investigators investigated the comparative outcomes of robotic and open surgery in the management of pancreatic cancer after NAT, exploring the feasibility and safety of robotic procedures in complex cases of pancreatic cancer, and providing evidence-based guidance for clinical practice.

Currently, most studies focus on upfront resectable pancreatic cancer, benign or low-grade malignant tumors, demonstrating that robotic surgery can shorten postoperative hospital stays, reduce intraoperative blood loss, and achieve oncological outcomes comparable to open surgery. The feasibility and safety of minimally invasive surgery in cases after NAT were unclear. Both the Miami international evidence-based consensus and the Brescia international validated European guidelines indicate that current data are insufficient to recommend minimally invasive approaches for pancreatic cancer resection following NAT, highlighting the need for additional research. Therefore, it is worth exploring the safety of robotic resection for pancreatic cancer following NAT. The investigators investigated the comparative outcomes of robotic and open surgery in the management of pancreatic cancer after NAT, exploring the feasibility and safety of robotic procedures in complex cases of pancreatic cancer, and providing evidence-based guidance for clinical practice.

Pancreatic Cancer
Neoadjuvant Therapy
Robotic Surgery

Robotic surgery

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2025-08-20	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-08-28
First Submitted that Met QC Criteria 2025-08-28	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2025-08-29
First Posted (ESTIMATED) 2025-08-29	Results First Posted N/A	Last Verified 2025-08

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Robotic surgery Patients who receive robotic pancreatic resection
: Open surgery Patients who receive open pancreatic resection

Primary Outcome Measures	Measure Description	Time Frame
Overall complication	The complication occurred within 90 days after the surgery	Until the 90 days after surgery

Secondary Outcome Measures	Measure Description	Time Frame
Clinically relevant postoperative pancreatic fistula	Grade B or C pancreatic fistula within 90 days after surgery	Until the 90 days after surgery
Postoperative pancreatectomy hemorrhage	Hemorrhage occurred within 90 days after surgery	Until the 90 days after surgery
Disease-free survival	The length of time from the completion of surgery until the recurrence of cancer, the occurrence of metastasis, death from any cause, or to the last follow-up.	Up to 2 years after the surgery
Overall survival	The length of time from the date of surgery to death from any cause or to the last follow-up.	Up to 2 years after surgery

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Age over 18 years.
Received neoadjuvant chemotherapy.
Postoperative pathology confirmed pancreatic cancer.
Underwent either open or robotic surgery.

Intraoperative discovery of unresectable tumor or presence of distant metastasis.
ASA score ≥ 4.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record